BNP Paribas Financial Markets Has $26,000 Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

BNP Paribas Financial Markets lifted its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 116.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,753 shares of the company’s stock after acquiring an additional 3,101 shares during the quarter. BNP Paribas Financial Markets’ holdings in scPharmaceuticals were worth $26,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. The Manufacturers Life Insurance Company bought a new position in scPharmaceuticals during the 3rd quarter worth approximately $57,000. King Luther Capital Management Corp boosted its stake in shares of scPharmaceuticals by 0.9% during the 3rd quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock worth $10,150,000 after buying an additional 20,650 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of scPharmaceuticals by 1.4% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after buying an additional 14,866 shares during the last quarter. Rice Hall James & Associates LLC grew its position in shares of scPharmaceuticals by 25.0% in the 3rd quarter. Rice Hall James & Associates LLC now owns 621,665 shares of the company’s stock valued at $2,835,000 after acquiring an additional 124,438 shares during the period. Finally, Bank of Montreal Can acquired a new stake in scPharmaceuticals in the 2nd quarter valued at about $1,544,000. Institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Trading Up 2.4 %

Shares of scPharmaceuticals stock opened at $3.39 on Friday. The firm’s 50 day moving average is $3.81 and its 200 day moving average is $4.34. The firm has a market capitalization of $169.64 million, a PE ratio of -1.78 and a beta of 0.14. scPharmaceuticals Inc. has a 1 year low of $3.08 and a 1 year high of $6.71. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SCPH. Craig Hallum cut their price objective on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a research note on Thursday, November 14th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.